Published in
American Society of Hematology, Blood Advances, 20(3), p. 3002-3009, 2019
DOI: 10.1182/bloodadvances.2019000147
Links
Tools
Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone
Journal article published in 2019 by
Efstathios Kastritis 
,
Ioanna Dialoupi,
Maria Gavriatopoulou,
Maria Roussou,
Nikolaos Kanellias,
Despina Fotiou,
Ioannis Ntanasis-Stathopoulos ,
Elektra Papadopoulou,
Dimitrios C. Ziogas ,
Kimon Stamatelopoulos ,
Efstathios Manios,
Argyrios Ntalianis,
Evangelos Eleutherakis-Papaiakovou ,
Asimina Papanikolaou,
Magdalini Migkou
and other authors.
,
Ioanna Dialoupi,
Maria Gavriatopoulou,
Maria Roussou,
Nikolaos Kanellias,
Despina Fotiou,
Ioannis Ntanasis-Stathopoulos ,
Elektra Papadopoulou,
Dimitrios C. Ziogas ,
Kimon Stamatelopoulos ,
Efstathios Manios,
Argyrios Ntalianis,
Evangelos Eleutherakis-Papaiakovou ,
Asimina Papanikolaou,
Magdalini Migkou
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Postprint:
archiving forbidden
Data provided by 
Abstract
Key Points Bortezomib with dexamethasone and low-dose lenalidomide is an active therapy for previously untreated patients with AL amyloidosis. VRD can induce MRD-negative responses, but nonhematologic toxicity may be significant in patients with advanced disease.